Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

BCMA-målrettede LCAR-BCDR-celler hos pasienter med residiverende/refraktært myelomatose

20. september 2026 oppdatert av: Weijun Fu, Shanghai Changzheng Hospital

En klinisk fase I-studie for å evaluere sikkerheten, toleransen og effekten av BCMA-målrettet LCAR-BCDR-celleprodukt hos pasienter med residiverende/refraktært myelomatose

This is a prospective, single-arm, open-label, dose-finding and dose-expansion study that evaluates the safety, tolerability, PK, and anti-tumor efficacy of LCAR-BCDR cell preparations in relapsed/refractory multiple myeloma subjects who received adequate standard therapy.

Studieoversikt

Status

Fullført

Intervensjon / Behandling

Detaljert beskrivelse

The research plan stipulates that "four dose groups will be conducted, namely 30×10^6, 100×10^6, 200×10^6, and 400×10^6". The research team held a SET meeting and decided to increase the dose escalation to 600×10^6 and 800×10^6, and obtained ethical approval from all sites.

Studietype

Intervensjonell

Registrering (Faktiske)

24

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Shanghai, Kina
        • Shanghai Changzheng Hospital
      • Shanghai, Kina
        • Shanghai Fourth People's Hospital Affiliated to Tongji University
      • Tianjin, Kina
        • Institute of Hematology & Blood Diseases Hospital
      • Wenzhou, Kina
        • The First Affiliated Hospital of Wenzhou Medical University
    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina
        • Beijing Boren Hospital
    • Zhejiang
      • Hangzhou, Zhejiang, Kina
        • Zhejiang Provincial People's Hospital

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. The subject voluntarily participates in the clinical study; Fully understand and be Informed of the study and sign the Informed consent (Informed Consent Form, ICF); Willing to follow and able to complete all test procedures; Informed consent must be obtained before initiating any tests or procedures related to the study that are not part of the standard treatment of the subject's disease;
  2. Subjects ≥ 18 years of age.
  3. Documented initial diagnosis of MM according to IMWG diagnostic criteria.
  4. Presence of measurable disease at screening.
  5. Received a PI and an IMiD (except thalidomide).
  6. Received at least 3 prior lines of therapy for multiple myeloma, undergone at least 1 complete cycle of treatment for each line, unless progressive disease (PD) was documented by IMWG criteria as the best response to the regimen. Also, subjects refractory or intolerant to any PI and any IMiD in their previous treatment afterwards are eligible.
  7. Expected survival ≥ 3 months.
  8. Clinical laboratory values meet screening visit criteria
  9. Fertile women must be negative using a highly sensitive serum pregnancy test (β human chorionic gonadotropin [β -HCG]) at screening time and before initial treatment with cyclophosphamide and fludarabine;

Exclusion Criteria:

  1. No response to prior BCMA-targeted CAR-T therapy (except in subjects who relapsed after CR to prior CAR-T treatment).
  2. Prior treatment with any antibody targeting BCMA.
  3. Diagnosed or pretreated for an invasive malignancy other than multiple myeloma.
  4. Prior anti-tumor treatment (before pretreatment) with insufficient washout period.
  5. Known active, or prior history of central nervous system (CNS) involvement, or clinical signs of membrane/spinal membrane involvement of multiple myeloma.
  6. Positive of any hepatitis B surface antigen (HBsAg), hepatitis B virus deoxyribonucleic acid (HBV DNA), hepatitis C antibody (HCV-Ab), hepatitis C virus ribonucleic acid (HCV RNA), human immunodeficiency virus antibody (HIV-Ab) at the time of screening.
  7. Serious underlying medical conditions
  8. Male subjects who have a birth plan during the study period or within 1 year after the study treatment.
  9. Female subjects who are pregnant, breast-feeding, or plan to become pregnant during the study period or within 1 year after the study treatment.
  10. The investigator considered that the subjects were not suitable for any conditions of participation in the study.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: LCAR-BCDR cells product

Each subject will receive LCAR-BCDR cells

Before treatment with LCAR-BCDR cells, subjects will receive a conditioning regimen

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence, severity, and type of treatment-emergent adverse events (TEAEs)
Tidsramme: Minimum 2 years after LCAR-BCDR infusion (Day 1)

An adverse event refers to any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product (investigational or non-investigational), which does not necessarily have a causal relationship with the treatment.

Minimum 2 years after LCAR-BCDR infusion (Day 1)
Recommended Phase 2 dose (RP2D) finding
Tidsramme: 30 days after LCAR-BCDR infusion (Day 1)

RP2D established through ATD+BOIN design

30 days after LCAR-BCDR infusion (Day 1)
CAR positive T cells in peripheral blood and bone marrow
Tidsramme: Minimum 2 years after LCAR-BCDR infusion (Day 1)

CAR positive T cells in peripheral blood and bone marrow after LCAR-BCDR infusion

Minimum 2 years after LCAR-BCDR infusion (Day 1)
CAR transgene levels in peripheral blood and bone marrow
Tidsramme: Minimum 2 years after LCAR-BCDR infusion (Day 1)

CAR transgene levels in peripheral blood and bone marrow after LCAR-BCDR infusion

Minimum 2 years after LCAR-BCDR infusion (Day 1)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Overall Response Rate (ORR)
Tidsramme: Minimum 2 years after LCAR-BCDR infusion (Day 1)

The ORR is defined as the percentage of participants who achieve partial response (PR) or better according to international myeloma working group (IMWG) criteria.

Minimum 2 years after LCAR-BCDR infusion (Day 1)
Progression-free survival (PFS)
Tidsramme: Minimum 2 years after LCAR-BCDR infusion (Day 1)

Progression Free Survival (PFS) is defined as the time from the date of first infusion of the LCAR-BCDR to the first documented disease progression (according to IMWG criteria) or death (due to any cause), whichever occurs first

Minimum 2 years after LCAR-BCDR infusion (Day 1)
Overall Survival (OS)
Tidsramme: Minimum 2 years after LCAR-BCDR infusion (Day 1)

Overall Survival (OS) is defined as the time from the date of first infusion of LCAR-AIO to death of the subject

Minimum 2 years after LCAR-BCDR infusion (Day 1)
Incidence of anti-LCAR-BCDR antibody
Tidsramme: Minimum 2 years after LCAR-BCDR infusion (Day 1)

Venous blood samples will be collected to measure LCAR-BCDR positive cell concentrations and the transgenic level of LCAR-BCDR, at the time points when anti-LCAR-BCDR antibody serum samples are evaluated

Minimum 2 years after LCAR-BCDR infusion (Day 1)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. september 2022

Primær fullføring (Faktiske)

27. mai 2025

Studiet fullført (Faktiske)

27. mai 2025

Datoer for studieregistrering

Først innsendt

12. mai 2022

Først innsendt som oppfylte QC-kriteriene

12. mai 2022

Først lagt ut (Faktiske)

17. mai 2022

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

22. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

20. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere